Market Access/ News/ News FDA rejection of Spero’s tebipenem ‘raises resistance threat’ Phil Taylor antibiotic, antimicrobial resistance, fda, regulatory, Spero Therapeutics, tebipenem 0 Comment The FDA’s decision not to approve Spero Therapeutics’ oral antibiotic tebipenem Hbr for adults with complicated urinary tract Share X FDA rejection of Spero’s tebipenem ‘raises resistance threat’ https://pharmaphorum.com/news/fda-rejection-of-speros-tebipenem-raises-resistance-threat/